A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

NCT05107128 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington's Disease

Interventions

DRUG: SAGE-718
DRUG: Placebo

Sponsor

Supernus Pharmaceuticals, Inc.